Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab

Executive Summary

One of Teva's few bright spots is its leading position in the big new commercial opportunity for migraine, but its CGRP drug fremanezumab could now be delayed by an issue at third-party manufacturer Celltrion.

Advertisement

Related Content

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Teva Pushes CGRP Timeline Back To End Of 2018
Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Ex-Teva Executive To Steer Dr Reddy’s As COO
FDA Warning Letter Calls Attention to Celltrion's 'Poor' Aseptic Practices
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel